The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 7)
Access to Data and Biospecimens, 2014
Increased inflammation is associated with the progression and possibly even onset of Parkinson's disease (PD). Mutations in the LRRK2 gene are also associated with PD, and recent evidence points to a role for LRRK2 to modulate inflammatory pathways. This project aims to investigate inflammatory cytokines (small proteins involved in cell signaling) in people with LRRK2 mutations...
Rapid Response Innovation Awards, 2010
- In animal models of PD, brain injections of certain neurotrophic factors prevent degeneration of midbrain dopaminergic neurons.
- Clinical testing of brain injected gene vectors expressing these neurotrophic factors is underway.
- Frequent intranasal dosing with neurotrophic factor (protein) is also therapeutic in animal models.
- This project will test whether a single intr
Researchers: Ian Andrew Ferguson, PhD, MBA
MJFF Research Grant, 2009
This study has two objectives:
1. To assess the occurrence and symptoms of anxiety disorders in Parkinson's disease, including atypical anxiety syndromes, and anxiety states associated with ‘off’ periods or periods of dyskinesias in patients with fluctuating response to medication.
2. To assess the properties of the most commonly used anxiety rating scales in Parkinson's dise...
Researchers: Albert F. G. Leentjens, MD, PhD
Rapid Response Innovation Awards, 2007
Mutations in PINK1 can cause Parkinson’s disease in certain familial PD cases. The exact cellular function of PINK1 and the impact of disease-relevant mutations remain unknown. PINK1 is known to function as a kinase but its cellular substrates remain to be identified.
In this project, Dr. Culvenor has isolated PINK1 protein and will utilize biochemical assays to identify physiologically relevant P...
Community Fast Track, 2006
Study of the Role of Phosphorylation at Ser 129 in Alpha-synuclein Induced Dopaminergic Neurodegeneration in a Rodent Model of Parkinson's Disease
The involvement of alpha-synuclein in Parkinson's disease neurodegeneration is now widely accepted. However, factors and events contributing to the alpha-synuclein toxicity are still being investigated. Among modifications of alpha-synuclein, phosphorylation at Serine 129 has been related to the disease process based on data from postmortem studies and in vitro experiments. In fact, a recent study...